Don’t Rush to Aprocitentan for Resistant Hypertension

December 2024

Aprocitentan (Tryvio) will be the first dual endothelin antagonist approved for resistant hypertension.

It blocks receptors of endothelin...a vasoconstrictor and mediator of aldosterone.

It’s similar to other endothelin receptor antagonists, such as bosentan (Tracleer)...but these are for pulmonary arterial hypertension.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote